Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Q2 2026 Earnings Presentation
17 slides from Botanix Pharmaceuticals's earnings presentation, Mar 3, 2026
Slide 1: Investor Update
rsonal use only Investor Update 27 January 2026 www.botanixpharma.com
Slide 2: Important Notices & Disclaimer
Important Notices & Disclaimer 1. Summary information The following notice and disclaimer applies to this investor presentation (“Presentation”) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Prese
Slide 3: Corporate overview: Growing dermatology pharmaceutical company with high physician satisfaction for Sofdra
Corporate overview: Growing dermatology pharmaceutical company with high physician satisfaction for Sofdra rsonal use only Dermatology Focused Innovative Platform Capital Position Positioned for Growth Sofdra® is the first and Fulfilment platform Cash of A$31.5 50 highly productive only new chemical
Slide 4: Botanix is led by an experienced group of dermatology executives
Botanix is led by an experienced group of dermatology executives >30 rsonal use only VINCE IPPOLITO HOWIE MCKIBBON CAREY HERBERT CHRIS LESOVITZ successful Executive Chairman Chief Legal & Compliance Officer Chief Financial Officer, U.S. dermatology Chief Executive Officer product launches developed,
Slide 5: Primary hyperhidrosis affects twice as many patients as psoriasis and is the third largest patient category in dermatology
Primary hyperhidrosis affects twice as many patients as psoriasis and is the third largest patient category in dermatology 16.1m rsonal use only US Population ~336m PRIMARY HYPERHIDROSIS PATIENTS Primary Hyperhidrosis ~16.1m Patients1 Primary Axillary Hyperhidrosis Patients1 ~10m 7.5m PSORIASIS PATI
Slide 6: Sofdra is the first and only new chemical entity for primary axillary hyperhidrosis, providing a safe and effective treatment option
Sofdra® is the first and only new chemical entity for primary axillary hyperhidrosis, providing a safe and effective treatment option Sofdra binds selectively to M3 FDA-Approved Indication2 receptors in the sweat gland, rsonal use only The treatment of primary axillary hyperhidrosis in adults blocks
Slide 7: The Botanix Fulfilment Platform offers an innovative approach with frictionless access to Sofdra
The Botanix Fulfilment Platform offers an innovative approach with frictionless access to Sofdra® for dermatologists and patients rsonal use only ü Seamless fulfilment Increase in reimbursed PRESCRIBER PATIENT PHARMACY WHOLESALER ü prescriptions CO-PAY DISCOUNT ü High refill adherence rates Consigne
Slide 8: Key accomplishments in last months from Sofdra launch to date
Key accomplishments in last 11 months from Sofdra launch to date Cumulative Gross Revenue Cumulative Net Revenue Cumulative Total Prescriptions 100 25 70 rsonal use only 60 80 $93.5 20 $21.2 50 62.5k 60 million 15 shipped million 40 thousands millions millions 10 30 40 20 20 5 10 0 0 0 CY2025 CY2025
Slide 9: Financial Results January 2026
rsonal use only Financial Results 27 January 2026 9 www.botanixpharma.com
Slide 10: Q2 FY2026: Strong Sofdra TRx growth and highlights
Q2 FY2026: Strong Sofdra® TRx growth and highlights rsonal use only 25,351 • Total prescriptions shipped grew 24% vs Q1 FY2026, driven by our TRx fulfilment platform and productive sales team $9.1m • Net revenue increased 28% quarter over quarter Net Revenue 24% • Gross to net yield continues to imp
Slide 11: Sofdra TRx shipments grew to 25,351 in Q2 FY26
Sofdra® TRx shipments grew to 25,351 in Q2 FY26 Growth in Volume of Total Prescriptions Shipped +24% rsonal use only 25.3k +50% 20.4k +323% 13.6k 3.2k Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY2026 Note: Data sourced from SendRx and subject to reconciliation, which may retroactively adjust figures; discrep
Slide 12: Net revenue is accelerating in step with prescription growth, while gross to net yield continues to improve
Net revenue is accelerating in step with prescription growth, while gross to net yield continues to improve Sofdra® Net Revenue GTN Yield* rsonal use only +28% 23% 24% $9.1M 21% $7.1m 15% $4.3m $0.7m Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY2026 Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY2026 *The Company aims to
Slide 13: 90% of surveyed healthcare professionals expect to increase Sofdra prescribing in the next six months
90% of surveyed healthcare professionals (HCPs) expect to increase Sofdra® prescribing in the next six months Is your prescribing of Sofdra likely to increase or rsonal use only decrease in the next 6 months? Percentage of Response Primary Drivers of Sofdra Prescriptions 86% • 35% Access/SendRx - 96
Slide 14: In market research physician comments regarding Sofdra and SendRx were overwhelmingly positive
In market research physician comments regarding Sofdra® and SendRx were overwhelmingly positive PATIENT ADHERENCE rsonal use only SWITCHING TO SOFDRA “People like it being similar to SENDRX PREFERENCE “I proactively bring up Sofdra, deodorant, because the habit has “I haven’t had any issues…if they
Slide 15: Q2 FY2026: Strong Financial Fundamentals
Q2 FY2026: Strong Financial Fundamentals rsonal use only $(17.2) • Operating net cash outflows increased by $4.1m, primarily due to Operating Cash the additional 23 sales professionals and associated one-time start- Outflow up costs, along with certain annual costs • Inventory balance is sufficient
Slide 16: Disciplined financial approach to cost management
Disciplined financial approach to cost management Cash flows from operating activities 31-Mar-25 30-Jun-25 30-Sep-25 31-Dec-25 % Change Q1 FY26 to Q2 FY26 Receipt from Royalties 218 195 504 435 Receipts from product sales, net of fees 326 3,836 8,271 11,890 n Receipts from sales increased 44% Paymen
Slide 17: Three key pillars drive Botanix's near- and long-term value
Three key pillars drive Botanix’s near- and long-term value rsonal use only Strong Opportunity Differentiated Solid Foundation for for Sofdra® Fulfilment Platform Growth & Profitability • Large underserved market of • Improves gross to net yield • Manufacturing efficiencies 10 million patients incre
Botanix Pharmaceuticals — Q2 2026 Earnings Presentation on 6ix